Acetaminophen Overdose: New Research & Hidden Dangers of Common Painkiller

The conversation around acetaminophen – commonly known as Tylenol – and neurodevelopmental conditions like autism has intensified in recent months, fueled by social media and news reports. While concerns about a potential link are understandable, medical experts emphasize a far more immediate and documented danger associated with this widely used medication: accidental overdose and the resulting liver damage. Understanding this distinction is crucial for public health, especially given acetaminophen’s ubiquitous presence in medicine cabinets.

The Scale of Acetaminophen Poisoning

Acetaminophen poisoning represents a significant public health challenge in the United States. According to Kennon Heard, MD, PhD, a professor in the CU Anschutz Department of Emergency Medicine and section chief of medical toxicology, it’s a leading cause of hospitalization and death related to non-prescription drugs. Each year, approximately 56,000 people require emergency department visits due to acetaminophen poisoning, with around 2,600 hospitalizations. The drug is implicated in nearly half of all acute liver failure cases in the U.S. And contributes to roughly 20% of liver transplants nationwide. CU Anschutz researchers have been at the forefront of studying and addressing this issue for decades.

Dr. Heard, who has dedicated over 25 years to researching acetaminophen poisoning, is currently leading a clinical trial exploring a novel approach to mitigate liver damage in severe overdose cases. This trial investigates the leverage of fomepizole, a medication typically used to treat antifreeze poisoning, as a potential antidote.

Why Overdoses Occur: A Multifaceted Problem

Acetaminophen, the active ingredient in Tylenol and numerous store-brand pain relievers, has a long history of safe use when taken as directed. But, problems arise when individuals exceed recommended dosages, either through a single large dose or repeated overconsumption over time. The medication is also a common component in over-the-counter cold, flu, sinus, and menstrual pain remedies, increasing the risk of unintentional double-dosing.

“There are cases where people accidentally take too much acetaminophen,” Dr. Heard explains. “Or maybe they have a really bad toothache, and they think if two is decent, four is better, eight is even better, and so on. Or it’s someone who’s taking multiple repeated overdoses. Those are the people who get into trouble.”

Beyond accidental overdoses, acetaminophen is frequently involved in suicide attempts and self-harm incidents. As Dr. Heard points out, “The No. 1 rule at the Poison Center is that if it’s available, people will take it, and a lot of people have Tylenol in their medicine chest.” This accessibility underscores the importance of safe storage and responsible use.

Limitations of the Current Antidote and a Recent Approach

For decades, acetylcysteine has been the standard antidote for acetaminophen overdose, effectively preventing serious liver damage when administered promptly. However, its efficacy diminishes significantly if treatment is delayed beyond eight hours after the overdose. This time sensitivity presents a critical challenge, as many patients don’t seek medical attention until liver injury has already begun, rendering acetylcysteine less effective.

To address this limitation, Dr. Heard and his colleagues are investigating fomepizole, a drug approved for treating poisoning from ethylene glycol and methanol – substances found in antifreeze. The FDA recently initiated a label change process for acetaminophen to reflect emerging evidence regarding potential links to neurological conditions, but the immediate risk of overdose remains a primary concern.

Fomepizole works by blocking enzymes that convert these toxic substances into harmful byproducts. Research suggests it may also be beneficial in acetaminophen overdose cases, particularly severe ones, dating back to the 1990s. Increasingly, doctors have been using fomepizole “off-label” – meaning for a purpose not specifically approved by the FDA – to treat serious acetaminophen poisoning.

A “Proof of Concept” Clinical Trial

The ongoing phase II clinical trial, led by Dr. Heard, aims to determine whether combining fomepizole with standard acetylcysteine treatment can reduce liver damage in high-risk patients following an acetaminophen overdose. This is considered a “proof of concept” study, designed to assess whether the combination demonstrates sufficient promise to warrant larger, more comprehensive trials.

Participants are randomly assigned to receive either both medications or acetylcysteine alone in a double-blind study, meaning neither patients nor researchers know who is receiving which treatment until the trial concludes. Researchers will compare liver enzyme levels to assess whether fomepizole provides additional protection beyond the standard treatment.

Enrollment is currently underway at Denver Health, UCHealth University of Colorado Hospital, Children’s Hospital Colorado, and other sites. While enrollment has been slower than anticipated due to the difficulty of identifying eligible patients, researchers hope to enroll approximately 40 participants within the next 12 to 18 months. Positive findings could pave the way for a larger trial to evaluate long-term outcomes, including survival rates and the need for liver transplants.

Navigating the Acetaminophen Landscape: A Call for Caution

Dr. Heard’s primary message is a straightforward one: “People should carefully read medication labels, avoid exceeding recommended doses, and recognize that acetaminophen may be present in multiple products at home.” He emphasizes that a significant number of accidental overdoses occur alongside intentional overdoses, highlighting the need for increased awareness and responsible medication practices.

The recent attention surrounding a possible link between acetaminophen use during pregnancy and neurodevelopmental conditions is vital to acknowledge. CU Anschutz developmental pediatricians have noted that acetaminophen remains the only over-the-counter drug approved for fever reduction during pregnancy, and high fevers pose risks to developing fetuses. However, the immediate and well-established danger of acetaminophen overdose warrants continued focus and preventative measures.

Collaboration on this study includes Richard Dart, MD, PhD, and Andrew Monte, MD, PhD, both professors of emergency medicine. The research builds on decades of work conducted at CU Anschutz and Denver Health, solidifying their position as leaders in acetaminophen research.

What comes next: Researchers will continue to analyze data from the ongoing clinical trial, with results expected in the coming years. Further studies will be needed to confirm these findings and determine the optimal use of fomepizole in acetaminophen overdose cases. Public health campaigns emphasizing safe medication practices and responsible storage remain crucial in mitigating the risks associated with this widely used drug.